Sartorius AG
XETRA:SRT

Watchlist Manager
Sartorius AG Logo
Sartorius AG
XETRA:SRT
Watchlist
Price: 175.8 EUR 4.64% Market Closed
Market Cap: 12.1B EUR
Have any thoughts about
Sartorius AG?
Write Note

Sartorius AG
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius AG
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius AG
XETRA:SRT
Current Portion of Long-Term Debt
€98.8m
CAGR 3-Years
-35%
CAGR 5-Years
-10%
CAGR 10-Years
11%
Carl Zeiss Meditec AG
XETRA:AFX
Current Portion of Long-Term Debt
€21.8m
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
24%
Stratec SE
XETRA:SBS
Current Portion of Long-Term Debt
€58.9m
CAGR 3-Years
53%
CAGR 5-Years
35%
CAGR 10-Years
43%
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Current Portion of Long-Term Debt
€9.2m
CAGR 3-Years
47%
CAGR 5-Years
24%
CAGR 10-Years
4%
Siemens Healthineers AG
XETRA:SHL
Current Portion of Long-Term Debt
€2.4B
CAGR 3-Years
1%
CAGR 5-Years
89%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Current Portion of Long-Term Debt
€40.5m
CAGR 3-Years
11%
CAGR 5-Years
-10%
CAGR 10-Years
-10%
No Stocks Found

Sartorius AG
Glance View

Market Cap
12.1B EUR
Industry
Health Care

Sartorius AG is a globally recognized leader in the biopharmaceutical and laboratory equipment sectors, dedicated to enhancing the efficiency of research and production processes. Founded in 1870 and headquartered in Göttingen, Germany, this innovative company provides a comprehensive range of products and services that support the life sciences industry—from advanced laboratory instruments to high-quality access materials for biopharmaceutical manufacturing. As the demand for biotechnological solutions continues to rise, particularly in response to global health challenges, Sartorius stands out by offering critical tools and technologies, positioning itself at the forefront of a thriving market with sustainable growth potential. Investors will find Sartorius particularly attractive due to its robust business model, marked by significant investments in research and development that fuel continuous innovation. The company has experienced impressive revenue growth, bolstered by strategic acquisitions that expand its technological capabilities and market reach. With a committed focus on sustainability and efficiency, Sartorius not only drives profitability but also aligns with the growing investor preference for socially responsible enterprises. As healthcare demands increase and the biopharmaceutical industry evolves, Sartorius AG offers a compelling investment opportunity characterized by a strong market position, strategic foresight, and a commitment to improving human health across the globe.

SRT Intrinsic Value
190.01 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Sartorius AG's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
98.8m EUR

Based on the financial report for Sep 30, 2024, Sartorius AG's Current Portion of Long-Term Debt amounts to 98.8m EUR.

What is Sartorius AG's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
11%

Over the last year, the Current Portion of Long-Term Debt growth was -70%. The average annual Current Portion of Long-Term Debt growth rates for Sartorius AG have been -35% over the past three years , -10% over the past five years , and 11% over the past ten years .

Back to Top